Shorter Versus Standard Antithyroid Drug Therapy in Graves' Disease with Lower Baseline Thyrotropin Receptor Antibody (TRAb) Levels: Relapse Outcomes from a Propensity-Weighted Analysis
{{output}}
Background: The optimal duration of antithyroid drug (ATD) therapy in Graves' disease is uncertain. Although guidelines recommend 12-18 months, shorter courses may be sufficient in selected patients. We evaluated whether ATD dur... ...
